Bringing the Oncology Community Together

Dr. James Mohler Discusses Androgen-Deprivation Therapy

James Mohler, MD
Published Online: Tuesday, October 16, 2012
James Mohler, MD, Associate Director and Senior-Vice President for Translational Research, Chair, Department of Urology, Professor of Oncology, Roswell Park Cancer Institute, discusses androgen-deprivation therapy (ADT), a standard treatment for men with metastatic prostate cancer.

Mohler believes ADT should only be used to prevent a death from prostate cancer. Before administering ADT, strict calculations should be performed to determine if the cancer is life threatening. Mohler suggests weighing tumor growth rate, tumor volume, health, family history, and age before administering ADT, in order to have a complete knowledge of the risks and benefits associated with treatment.

Additionally, the treatment modality has a substantial impact on the efficacy of ADT. Various methods should be discussed as part of a treatment plan, including whether treatment should be continuous or intermittent, with or without an antiandrogen, or with surgical intervention or an LHRH agonist.

Mohler believes the decision to begin ADT is often rushed, following a prostatectomy or radiation therapy. He believes that in the era of personalized medicine it is important to consider individual characteristics, to determine the most appropriate treatment.

Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.